BioWorld

May 18, 2010

Astellas Acquires OSI for $4B; Sweetened Bid Melts Hostility

After an unsuccessful $3.5 billion hostile takeover attempt, Astellas Pharma Inc. raised its acquisition offer for OSI Pharmaceuticals Inc. to $4 billion, and OSI agreed to a friendly buyout. (BioWorld Today) Read More

ARCA Shares Get a Bounce on SPA OK for Beta-Blocker

Roxro Dodges Opioid, NSAID Traps; 'Smooth' Nod for Sprix

NewCo News: ElexoPharm's First License Deal Worth up to $41.6M from Merck

NuPathe Files for $86M IPO Ahead of Migraine Patch NDA

Clinic Roundup

Stock Movers

Other News To Note

ATS Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 15, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

LINC01116 has prognostic value in lung cancer, study shows

BioWorld MedTech

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...